Neurocrine Biosciences Inc vs SoundHound AI Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while SoundHound AI Inc trades at $6.56 (market cap $2.75B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.3× SoundHound AI Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SOUN | |
|---|---|---|
Market Cap | $17.40B | $2.75B |
Sector | Health | Technology |
52-Week High | $180.55 | $21.40 |
52-Week Low | $123.10 | $5.90 |
Enterprise Value | $16.49B | $2.54B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →